These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


295 related items for PubMed ID: 25127090

  • 1. Continuous subcutaneous hydrocortisone infusion therapy in Addison's disease: a randomized, placebo-controlled clinical trial.
    Gagliardi L, Nenke MA, Thynne TR, von der Borch J, Rankin WA, Henley DE, Sorbello J, Inder WJ, Torpy DJ.
    J Clin Endocrinol Metab; 2014 Nov; 99(11):4149-57. PubMed ID: 25127090
    [Abstract] [Full Text] [Related]

  • 2. Circadian hormone profiles and insulin sensitivity in patients with Addison's disease: a comparison of continuous subcutaneous hydrocortisone infusion with conventional glucocorticoid replacement therapy.
    Björnsdottir S, Øksnes M, Isaksson M, Methlie P, Nilsen RM, Hustad S, Kämpe O, Hulting AL, Husebye ES, Løvås K, Nyström T, Bensing S.
    Clin Endocrinol (Oxf); 2015 Jul; 83(1):28-35. PubMed ID: 25400085
    [Abstract] [Full Text] [Related]

  • 3. Continuous subcutaneous hydrocortisone infusion versus oral hydrocortisone replacement for treatment of addison's disease: a randomized clinical trial.
    Oksnes M, Björnsdottir S, Isaksson M, Methlie P, Carlsen S, Nilsen RM, Broman JE, Triebner K, Kämpe O, Hulting AL, Bensing S, Husebye ES, Løvås K.
    J Clin Endocrinol Metab; 2014 May; 99(5):1665-74. PubMed ID: 24517155
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. A Phase 2 Study of Continuous Subcutaneous Hydrocortisone Infusion in Adults With Congenital Adrenal Hyperplasia.
    Nella AA, Mallappa A, Perritt AF, Gounden V, Kumar P, Sinaii N, Daley LA, Ling A, Liu CY, Soldin SJ, Merke DP.
    J Clin Endocrinol Metab; 2016 Dec; 101(12):4690-4698. PubMed ID: 27680873
    [Abstract] [Full Text] [Related]

  • 6. Improvement of anthropometric and metabolic parameters, and quality of life following treatment with dual-release hydrocortisone in patients with Addison's disease.
    Giordano R, Guaraldi F, Marinazzo E, Fumarola F, Rampino A, Berardelli R, Karamouzis I, Lucchiari M, Manetta T, Mengozzi G, Arvat E, Ghigo E.
    Endocrine; 2016 Feb; 51(2):360-8. PubMed ID: 26184416
    [Abstract] [Full Text] [Related]

  • 7. Salivary cortisol day curves in assessing glucocorticoid replacement therapy in Addison's disease.
    Smans L, Lentjes E, Hermus A, Zelissen P.
    Hormones (Athens); 2013 Feb; 12(1):93-100. PubMed ID: 23624135
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Salivary cortisol day curves in Addison's disease in patients on hydrocortisone replacement.
    Ross IL, Levitt NS, Van der Walt JS, Schatz DA, Johannsson G, Haarburger DH, Pillay TS.
    Horm Metab Res; 2013 Jan; 45(1):62-8. PubMed ID: 22893258
    [Abstract] [Full Text] [Related]

  • 10. Pulsatile thyrotropin secretion in patients with Addison's disease during variable glucocorticoid therapy.
    Hangaard J, Andersen M, Grodum E, Koldkjaer O, Hagen C.
    J Clin Endocrinol Metab; 1996 Jul; 81(7):2502-7. PubMed ID: 8675567
    [Abstract] [Full Text] [Related]

  • 11. Low-dose hydrocortisone replacement improves wellbeing and pain tolerance in chronic pain patients with opioid-induced hypocortisolemic responses. A pilot randomized, placebo-controlled trial.
    Nenke MA, Haylock CL, Rankin W, Inder WJ, Gagliardi L, Eldridge C, Rolan P, Torpy DJ.
    Psychoneuroendocrinology; 2015 Jun; 56():157-67. PubMed ID: 25827960
    [Abstract] [Full Text] [Related]

  • 12. Current and emerging therapies for Addison's disease.
    Napier C, Pearce SH.
    Curr Opin Endocrinol Diabetes Obes; 2014 Jun; 21(3):147-53. PubMed ID: 24755997
    [Abstract] [Full Text] [Related]

  • 13. Salivary Cortisol and Cortisone do not Appear to be Useful Biomarkers for Monitoring Hydrocortisone Replacement in Addison's Disease.
    Ross IL, Lacerda M, Pillay TS, Blom DJ, Johannsson G, Dave JA, Levitt NS, Haarburger D, van der Walt JS.
    Horm Metab Res; 2016 Dec; 48(12):814-821. PubMed ID: 27813051
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Effect of a pre-exercise hydrocortisone dose on short-term physical performance in female patients with primary adrenal failure.
    Simunkova K, Jovanovic N, Rostrup E, Methlie P, Øksnes M, Nilsen RM, Hennø H, Tilseth M, Godang K, Kovac A, Løvås K, Husebye ES.
    Eur J Endocrinol; 2016 Jan; 174(1):97-105. PubMed ID: 26494876
    [Abstract] [Full Text] [Related]

  • 17. Altered chemokine Th1/Th2 balance in Addison's disease: relationship with hydrocortisone dosing and quality of life.
    Ekman B, Alstrand N, Bachrach-Lindström M, Jenmalm MC, Wahlberg J.
    Horm Metab Res; 2014 Jan; 46(1):48-53. PubMed ID: 23918683
    [Abstract] [Full Text] [Related]

  • 18. Long-term use of continuous subcutaneous hydrocortisone infusion therapy in patients with congenital adrenal hyperplasia.
    Mallappa A, Nella AA, Sinaii N, Rao H, Gounden V, Perritt AF, Kumar P, Ling A, Liu CY, Soldin SJ, Merke DP.
    Clin Endocrinol (Oxf); 2018 Oct; 89(4):399-407. PubMed ID: 30003563
    [Abstract] [Full Text] [Related]

  • 19. 24-Hour Profiles of 11-Oxygenated C19 Steroids and Δ5-Steroid Sulfates during Oral and Continuous Subcutaneous Glucocorticoids in 21-Hydroxylase Deficiency.
    Turcu AF, Mallappa A, Nella AA, Chen X, Zhao L, Nanba AT, Byrd JB, Auchus RJ, Merke DP.
    Front Endocrinol (Lausanne); 2021 Oct; 12():751191. PubMed ID: 34867794
    [Abstract] [Full Text] [Related]

  • 20. Glucocorticoid replacement is permissive for rapid eye movement sleep and sleep consolidation in patients with adrenal insufficiency.
    García-Borreguero D, Wehr TA, Larrosa O, Granizo JJ, Hardwick D, Chrousos GP, Friedman TC.
    J Clin Endocrinol Metab; 2000 Nov; 85(11):4201-6. PubMed ID: 11095454
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 15.